Results for this period
First quarter1 April 2026 to 30 June 2026Non-consolidated (standalone)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
The company pursued research and development aimed at creating novel cancer immunotherapy drugs. Regarding its financial position, it said that spending related to research and development was the main factor behind the decrease in cash and deposits.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (standalone) |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | ¥0 million (YoY -66.7%) |
| Operating profit | ¥-547 million |
| Ordinary income | ¥-545 million |
| Profit attributable to owners of the parent | ¥-530 million |
| Net income per share | △¥3.82 |
| Equity ratio | End of the current fiscal period 89.8 / End of previous period 90.1 |
| Total assets | ¥2,024 million |
| Net assets | ¥1,822 million |
| Full-year earnings forecast | Net Sales ¥0 million / Operating profit ¥-1,965 million / Ordinary income ¥-1,947 million / Net income ¥-1,949 million |
| Annual Dividend Forecast | ¥0.00 → ¥0.00 |
| Impairment loss | No impairment loss in the current first quarter (— thousand yen). No applicable assets. |
| Breakdown of extraordinary income (loss) | Extraordinary income Item Gain on sale of non-current assets / Amount ¥659 thousand, Item Gain on reversal of subscription rights to shares / Amount ¥15,342 thousand / Extraordinary loss Item Other / Amount ¥0 thousand |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Material subsequent events | No applicable matters. |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | None (対象者：Not applicable) |
| Issued Shares at Period-End | 138,891,300 shares |
| Treasury Shares at Period-End | 81 shares |
| Factors Behind Changes in Business Performance | The company pursued research and development aimed at creating novel cancer immunotherapy drugs. Regarding its financial position, it said that spending related to research and development was the main factor behind the decrease in cash and deposits. |
Items this document does not state (14)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company stated that it pursued research and development aimed at creating novel cancer immunotherapy drugs. Regarding its financial position, it said that spending related to research and development was the main factor behind the decrease in cash and deposits, but did not specify the direct factors behind the increase in the loss.